Moreover, several studies have shown that ITGA3 maintains aberrant expression in various types of cancer, including prostate cancer, intrahepatic cholangiocarcinoma, melanoma, pancreatic cancer, squamous cell carcinoma of the tongue, breast cancer, and colorectal cancer [50,51]. This evidence concerns the gene ITGA3 and prostate carcinoma.